摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dimethyl 1-benzyl-3,5-dimethyl-4-oxopiperidine-3,5-dicarboxylate | 862283-46-3

中文名称
——
中文别名
——
英文名称
dimethyl 1-benzyl-3,5-dimethyl-4-oxopiperidine-3,5-dicarboxylate
英文别名
——
dimethyl 1-benzyl-3,5-dimethyl-4-oxopiperidine-3,5-dicarboxylate化学式
CAS
862283-46-3
化学式
C18H23NO5
mdl
——
分子量
333.384
InChiKey
BCZIWFDIIQZRIG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    423.2±45.0 °C(Predicted)
  • 密度:
    1.172±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    72.9
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • Pharmaceutically active compounds
    申请人:Calabrese Antony Andrew
    公开号:US20050176772A1
    公开(公告)日:2005-08-11
    The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
    本发明涉及一类通式(I)所示的黑素皮质素MCR4激动剂,其中R1、R2、R3、R4和R5如本文所定义,特别涉及选择性MCR4激动剂化合物,它们在医学上的应用,含有它们的组合物,用于它们制备的工艺以及用于这些工艺的中间体。
  • [EN] PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA<br/>[FR] INHIBITEURS PURIQUES DE LA PHOSPHATIDYLINOSITOL 3-KINASE DELTA HUMAINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2017000125A1
    公开(公告)日:2017-01-05
    Provided are compounds of formula (I) or a pharmaceutically acceptable salts or stereoisomer thereof, which are PI3K-delta inhibitors, and are useful for the treatment of PI3K-delts-mediated diseases such as inflammation, asthma, COPD and cancer.
    提供的是式(I)的化合物或其药用可接受的盐或立体异构体,它们是PI3K-δ抑制剂,可用于治疗由PI3K-δ介导的疾病,如炎症、哮喘、慢性阻塞性肺病和癌症。
  • (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
    申请人:Pfizer Inc
    公开号:US07649002B2
    公开(公告)日:2010-01-19
    The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
    本发明涉及一类黑素细胞激素MCR4激动剂,其一般式为(I),其中R1、R2、R3、R4和R5如本文所定义,特别是选择性MCR4激动剂化合物,它们在医学上的使用,包含它们的组合物,制备它们的过程以及用于这种过程的中间体。
  • Purine inhibitors of human phosphatidylinositol 3-kinase delta
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US10221178B2
    公开(公告)日:2019-03-05
    The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    本发明提供的式 I 化合物是 PI3K-delta 抑制剂,因此可用于治疗 PI3K-delta 介导的疾病,如炎症、哮喘、慢性阻塞性肺病和癌症。
  • TRPA1 modulators
    申请人:Algomedix, Inc.
    公开号:US10428049B2
    公开(公告)日:2019-10-01
    This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.
    本公开涉及可用作 TRPA1 调节剂的多环杂芳族化合物,以及包含该化合物的治疗疼痛的组合物和方法。
查看更多